Patent US3503850A successfully refreshed from Google Patents.
US5162430A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Collagen-polymer conjugates
Assignee: Angiodevice International GmbH
•
Filing: 1989-11-14
•
Granted: 1992-11-10
•
Expires: 2009-11-14
Abstract
Abstract Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer.
Inventors
- 👤 Woonza Rhee
- 👤 Donald G. Wallace
- 👤 Alan S. Michaels
- 👤 Ramon A. Burns, Jr.
- 👤 Louis Fries
- 👤 Frank DeLustro
- 👤 Hanne Bentz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 06:57
CPC Classifications
C; C08; C08L; C08L89/00; C08L89/04; C08L89/06; A; A61; A61K; A61K47/00; A61K47/50; A61K47/51; A61K47/56; A61K47/59; A61K47/60; A61K47/61; A61K47/62; A61K47/64; A61K47/6435; A61L; A61L15/00; A61L15/16; A61L15/22; A61L15/225; A61L24/00; A61L24/04; A61L24/10; A61L24/102; A61L26/00; A61L26/0009; A61L26/0028; A61L26/0033; A61L27/00; A61L27/14; A61L27/18; A61L27/20; A61L27/22; A61L27/24; A61L27/26; A61L27/28; A61L27/34; A61L27/40; A61L27/44; A61L27/50; A61L27/54; A61L29/00; A61L29/04; A61L29/043; A61L29/044; A61L29/045; A61L29/06; A61L29/14; A61L29/16; A61L31/00; A61L31/04; A61L31/041; A61L31/042; A61L31/043; A61L31/044; A61L31/08; A61L31/10; A61L31/12; A61L31/125; A61P; A61P17/00; A61P43/00; C07; C07K; C07K14/00; C07K14/435; C07K14/475; C07K14/495; C07K14/78; C08B; C08B37/00; C08B37/006; C08B37/0063; C08B37/0069; C08B37/0072; C08H; C08H1/00; C08H1/06; C09; C09J; C09J189/00; C09J189/04; C09J189/06; G; G02; G02B; G02B1/00; G02B1/04; G02B1/041; G02B1/043; A61F; A61F2/00; A61F2/02; A61F2/04; A61F2/06; A61F2/07; A61F2310/00; A61F2310/00005; A61F2310/00365; A61K38/00; A61L2300/00; A61L2300/20; A61L2300/252; A61L2300/40; A61L2300/412; A61L2300/414; A61L2300/426; A61L2300/60; A61L2300/62; A61L2300/80; A61L2300/802; A61L2430/00; A61L2430/16; C08L2666/00; C08L2666/02; Y; Y10; Y10S; Y10S525/00; Y10S525/937
Claims Analysis
Total Claims: 37
Claim 1
Independent Claim
15 words
A pharmaceutically acceptable, non-immunogenic composition comprising atelopeptide collagen chemically conjugated to a synthetic hydrophilic polymer.
Claim 2
Dependent Claim
15 words
A pharmaceutically acceptable, non-immunogenic composition comprising atelopeptide collagen chemically conjugated to a synthetic hydrophilic polymer.
Claim 3
Dependent Claim
23 words
The composition of claim 1 wherein the atelopeptide collagen is selected from the group consisting of type I, type II and type III.
Claim 4
Dependent Claim
23 words
The composition of claim 1 wherein said polymer is polyethylene glycol having a weight average molecular weight of about 400 to about 20,000.
Claim 5
Dependent Claim
20 words
The composition of claim 1 wherein said synthetic hydrophilic polymer is bound to an available lysine residue on said collagen.
Claim 6
Dependent Claim
31 words
The composition of claim 4 wherein said polymer has a first end and a second end, said first end being bound to said lysine residue, and said second end being non-bound.
Claim 7
Dependent Claim
19 words
The composition of claim 5 wherein synthetic hydrophilic polymer molecules are bound to 10-50% of said available lysine residues.
Claim 8
Dependent Claim
20 words
The composition of claim 6 wherein said synthetic hydrophilic polymer molecules are bound to 20-30% of said available lysine residues.
Claim 9
Dependent Claim
26 words
The composition of claim 4 wherein said polymer has a first end and a second end, wherein said first and second ends are bound to collagen.
Claim 10
Dependent Claim
20 words
The composition of claim 8 wherein the ratio of collagen molecules to polymer molecules is about 1:1 to about 1:20.
Claim 11
Dependent Claim
15 words
The composition of claim 8 wherein said collagen is atelopeptide fibrillar collagen or nonfibrillar collagen.
Claim 12
Dependent Claim
13 words
The composition of claim 1, wherein the synthetic hydrophilic polymer is polyethylene glycol.
Claim 13
Dependent Claim
14 words
The composition of claim 11 wherein the composition is a pharmaceutically acceptable injectable composition.
Claim 14
Dependent Claim
35 words
The composition of claim 1, wherein the synthetic hydrophilic polymer is polyethylene glycol having a molecular weight in the range of about 400 to about 20,000 and the composition is a pharmaceutically acceptable injectable composition.
Claim 15
Dependent Claim
38 words
A composition comprising: collagen chemically conjugated to a synthetic hydrophilic polymer having a first end and a second end, said first end being bound to a collagen molecule, and said second end being bound to a growth factor.
Claim 16
Dependent Claim
38 words
A composition comprising: collagen chemically conjugated to a synthetic hydrophilic polymer having a first end and a second end, said first end being bound to a collagen molecule, and said second end being bound to a growth factor.
Claim 17
Dependent Claim
71 words
The composition of claim 14 wherein said growth factor is selected from the group consisting of epidermal growth factor, transforming growth factor-α, transforming growth factor-β, transforming growth factor-β1, transforming growth factor-β2, platelet-derived growth factor-AA, platelet-derived growth factor-AB, platelet-derived growth factor-BB, acidic fibroblast growth factor, basic fibroblast growth factor, connective tissue activating peptide, β-thromboglobulin, insulin-like growth factors, tumor necrosis factor, interleukins, colony stimulating factors, erythropoietin, nerve growth factor, interferons, and osteogenic factors.
Claim 18
Dependent Claim
27 words
The composition of claim 15 wherein said growth factor is selected from the group consisting of transforming growth factor-β, transforming growth factor-β1, transforming growth factor-β2, and erythropoietin.
Claim 19
Dependent Claim
32 words
A pharmaceutically acceptable, non-immunogenic composition suitable for augmentation of soft tissue, which comprises: atelopeptide collagen chemically conjugated to a synthetic hydrophilic polymer; and a sufficient amount of a fluid pharmaceutically acceptable carrier.
Claim 20
Dependent Claim
32 words
A pharmaceutically acceptable, non-immunogenic composition suitable for augmentation of soft tissue, which comprises: atelopeptide collagen chemically conjugated to a synthetic hydrophilic polymer; and a sufficient amount of a fluid pharmaceutically acceptable carrier.
Claim 21
Dependent Claim
26 words
The composition of claim 17 wherein the polymer is polyethylene glycol and the collagen is selected from the group consisting of non-fibrillar collagen and fibrillar collagen.
Claim 22
Dependent Claim
23 words
The composition of claim 17 wherein said polymer is monomethyl-polyethylene glycol having a weight average molecular weight of about 1,900 to about 8,000.
Claim 23
Dependent Claim
22 words
The composition of claim 19 wherein said monomethyl-polyethylene glycol is chemically conjugated to 10-50% of the available lysine residues on said collagen.
Claim 24
Dependent Claim
26 words
The composition of claim 17 which further comprises a tissue growth-promoting amount of epidermal growth factor, transforming growth factor-β, an osteoinductive factor, or a hematopoietic factor.
Claim 25
Dependent Claim
49 words
The composition of claim 17 wherein said polymer has a first end and a second end, wherein said first and second ends are bound to collagen to form a crosslinked collagen-polymer conjugate, said composition having the form of a suspension of collagen-polymer conjugate particles in a pharmaceutically acceptable carrier.
Claim 26
Dependent Claim
32 words
The composition of claim 22 which further comprises a tissue growth-promoting amount of a growth factor selected from the group consisting of epidermal growth factor, transforming growth factor-β, or a hematopoietic factor.
Claim 27
Dependent Claim
42 words
The composition of claim 23 wherein said factor is chemically bound to said collagen by a covalent bond between said factor and the first end of said polymer, and a covalent bond between the second end of said polymer and said collagen.
Claim 28
Dependent Claim
20 words
The composition of claim 17 wherein said fluid carrier is present in an amount sufficient to render the composition malleable.
Claim 29
Dependent Claim
20 words
The composition of claim 17 wherein said fluid carrier is present in an amount sufficient to render the composition injectable.
Claim 30
Dependent Claim
67 words
A pharmaceutically acceptable, non-immunogenic, injectable composition suitable for augmentation of soft tissue, which comprises: atelopeptide collagen; a synthetic hydrophilic polymer having a first and second end, wherein said first and second ends comprise reactive groups capable of forming a covalent bond in situ with an available lysine side chain present in collagen; and a fluid pharmaceutically acceptable carrier in an amount sufficient to form an injectable composition.
Claim 31
Dependent Claim
67 words
A pharmaceutically acceptable, non-immunogenic, injectable composition suitable for augmentation of soft tissue, which comprises: atelopeptide collagen; a synthetic hydrophilic polymer having a first and second end, wherein said first and second ends comprise reactive groups capable of forming a covalent bond in situ with an available lysine side chain present in collagen; and a fluid pharmaceutically acceptable carrier in an amount sufficient to form an injectable composition.
Claim 32
Dependent Claim
23 words
The composition of claim 27 wherein said polymer comprises polyethylene glycol having a weight average molecular weight of about 400 to about 20,000.
Claim 33
Dependent Claim
12 words
The composition of claim 28 wherein said reactive groups comprise N-hydroxysuccinimide esters.
Claim 34
Dependent Claim
28 words
The composition of claim 27 wherein said composition comprises about 10 to about 100 mg/mL collagen and about 0.1 to about 30% synthetic hydrophilic polymer having reactive groups.
Claim 35
Dependent Claim
28 words
The composition of claim 30 wherein said composition comprises about 30 to about 80 mg/mL collagen and about 0.3 to about 10% synthetic hydrophilic polymer having reactive groups.
Claim 36
Dependent Claim
12 words
The composition of claim 27 wherein said collagen comprises fibrillar atelopeptide collagen.
Claim 37
Dependent Claim
11 words
The composition of claim 27 wherein said collagen comprises nonfibrillar collagen.
References Cited (Backward Citations)
US3619371A
Cited
US3788948A
Cited
US3876501A
Cited
US4055635A
Cited
US3960830A
Cited
US3949073A
Cited
US4088538A
Cited
US4488911A
Cited
US4002531A
Cited
US4192021A
Cited
US4261973A
Cited
US4563490A
Cited
US4314380A
Cited
US4415665A
Cited
US4414147A
Cited
US4412989A
Cited
US4357274A
Cited
US4495285A
Cited
US4495285B1
Cited
US4424208A
Cited
US4582640A
Cited
US4737544A
Cited
WO1984001106A1
Cited
US4592864A
Cited
US4496689A
Cited
US4678468A
Cited
US4687820A
Cited
US4557764A
Cited
US4563350A
Cited
US4935465A
Cited
US4689399A
Cited
US4732863A
Cited
US4642117A
Cited
US4766106A
Cited
WO1987004078A1
Cited
US4745180A
Cited
US4847325A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-11-10 | 1996-05-11 | 1996-11-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-11-10 | 2000-05-11 | 2000-11-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-11-10 | 2004-05-11 | 2004-11-10 | $7700.00 | Window Closed / Lapsed |